Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, A Parisi, Giancarlo Bisagni et al.|The Lancet Oncology|2022Cited by 50
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studiesFederica Miglietta, Valentina Guarneri, Maria Vittoria Dieci et al.|European Journal of Cancer|2023Cited by 14
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trialFrancesca Poggio, Lucia Del Mastro, Eva Blondeaux et al.|ESMO Open|2024Cited by 5
242MO Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studiesFederica Miglietta, Valentina Guarneri, Maria Vittoria Dieci et al.|Annals of Oncology|2023Cited by 2